Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Catalyst Pharmaceuticals

Top 3 Health Care Stocks You'll Regret Missing This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Catalyst Pharmaceuticals (CPRX) vs. Johnson & Johnson (JNJ): Predicting the Dominant Pharma Stock in 2024

Catalyst Pharmaceuticals (CPRX) vs. Johnson & Johnson (JNJ): Predicting the Dominant Pharma Stock in 2024

Within the realm of burgeoning technological innovation and its seamless integration, the pharmaceutical industry emerges as a focal point for investors. Given this perspective, which of the two pharma stocks, Catalyst Pharmaceuticals (CPRX) and Johnson & Johnson (JNJ), holds greater potential for enduring returns in 2024? Read on….

September Buy, Sell or Hold for This Pharma Sock: Catalyst Pharmaceuticals (CPRX)

September Buy, Sell or Hold for This Pharma Sock: Catalyst Pharmaceuticals (CPRX)

Catalyst Pharmaceuticals (CPRX) delivered a robust performance in its last reported quarter. So, is now the right entry point in the stock? Let’s look at its financial metrics to gauge its prospects.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Catalyst Pharmaceuticals (CPRX): Is Now the Time to Buy This Pharma Stock?

Catalyst Pharmaceuticals (CPRX) reported robust second-quarter results, with its topline reaching an all-time high. Does that mean it's time to buy the pharma stock now? Let’s look at its financial metrics to gauge its prospects….

Is Catalyst Pharmaceuticals (CPRX) a Buy in the Near Future?

Catalyst Pharmaceuticals (CPRX) witnessed significant bottom-line growth in the first quarter but missed expectations. Does the biopharmaceutical company deserve a place in your portfolio in the near future? Let’s look at its financial metrics to get an idea….

AbbVie (ABBV) and Catalyst Pharmaceuticals (CPRX): Analyzing Investment Potential

The pharmaceutical industry’s inelastic demand for its products helps it to weather economic downturns. With fears of an impending recession playing on the minds of investors, it could be wise to buy fundamentally strong pharmaceutical stock AbbVie (ABBV). On the other hand, given its mixed fundamentals and profitability, it could…

Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

Catalyst Pharmaceuticals's Return On Capital Employed Insights

Catalyst Pharmaceuticals's Return On Capital Employed Insights

According to Benzinga Pro data Catalyst Pharmaceuticals (NASDAQ:CPRX) posted a 9.88% decrease in earnings from Q3. Sales, however, increased by 6.55% over the previous quarter to $38.31 million.

Recap: Catalyst Pharmaceuticals Q4 Earnings

Recap: Catalyst Pharmaceuticals Q4 Earnings

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported its Q4 earnings results on Wednesday, March 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Earnings Preview For Catalyst Pharmaceuticals

Earnings Preview For Catalyst Pharmaceuticals

Catalyst Pharmaceuticals (NASDAQ:CPRX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-16. Here's what investors need to know before the announcement. Analysts estimate that Catalyst Pharmaceuticals will report an earnings per share (EPS) of $0.12.

Catalyst Pharmaceuticals: A Biotech Stock Worth Owning

Catalyst Pharmaceuticals: A Biotech Stock Worth Owning

Biopharmaceutical company Catalyst Pharmaceuticals (CPRX) has been advancing with the help of its product, FIRDAPSE. Furthermore, its top and bottom line grew in its last reported quarter. So, let’s discuss in detail why it could be wise to add CPRX to one’s portfolio now. Read on.

1

People

Steve Reitmeister

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Medical Pharmaceuticals

Arista Networks

Truist Securities

Vici Properties

Johnson Johnson JNJ

AvalonBay Communities

Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play